Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2024

Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2024

DelveInsight’s, “Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Methicillin-Resistant Staphylococcus Aureus Infections Understanding

Methicillin-Resistant Staphylococcus Aureus Infections: Overview

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most successful modern pathogens. The same organism that lives as a commensal and is transmitted in both health-care and community settings is also a leading cause of bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and hospital-acquired infections. Genetically diverse, the epidemiology of MRSA is primarily characterized by the serial emergence of epidemic strains. Although its incidence has recently declined in some regions, MRSA still poses a formidable clinical threat, with persistently high morbidity and mortality. Successful treatment remains challenging and requires the evaluation of both novel antimicrobials and adjunctive aspects of care, such as infectious disease consultation, echocardiography and source control.

""Methicillin-Resistant Staphylococcus Aureus Infections - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape is provided which includes the disease overview and Methicillin-Resistant Staphylococcus Aureus Infections treatment guidelines. The assessment part of the report embraces, in depth Methicillin-Resistant Staphylococcus Aureus Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Methicillin-Resistant Staphylococcus Aureus Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Methicillin-Resistant Staphylococcus Aureus Infections R&D. The therapies under development are focused on novel approaches to treat/improve Methicillin-Resistant Staphylococcus Aureus Infections.

Methicillin-Resistant Staphylococcus Aureus Infections Emerging Drugs Chapters

This segment of the Methicillin-Resistant Staphylococcus Aureus Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Methicillin-Resistant Staphylococcus Aureus Infections Emerging Drugs

• HY-004B8b: Helperby Therapeutics

Helperby has discovered and is developing a suite of Antibiotic Resistance Breakers (ARBs). These compounds, when combined with old antibiotics, can restore the original potency against both Gram positive and Gram negative bacteria. Helperby’s HY-004 project is in phase II trials for effectiveness against nasal MRSA decolonisation.

• TRL1068: Trellis Bioscience

TRL1068 is a high affinity mAb that targets the DNABII protein family; BLAST analysis has found hundreds of DNABII homologs across many bacterial species. TRL1068 is broad-spectrum, disrupting biofilm across multiple gram-positive and gram-negative bacteria species. Upon biofilm disruption, bacteria regain antibiotic susceptibility. The drug is currently in phase I stage of clinical trial evaluation to treat Methicillin-resistant Staphylococcus aureus infections. TRL1068 has received more than $5M in grant funding from the NIH to facilitate preclinical development, including multiple animal proof-of-concept experiments.

• Delpazolid (LCB01-0371): LegoChem Biosciences

Delpazolid (LCB01 0371) is an oxazolidinone derivative antibacterial therapeutic, being developed by LegoChem Biosciences to treat Tuberculosis, Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections.

Further product details are provided in the report……..

Methicillin-Resistant Staphylococcus Aureus Infections: Therapeutic Assessment

This segment of the report provides insights about the different Methicillin-Resistant Staphylococcus Aureus Infections drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Methicillin-Resistant Staphylococcus Aureus Infections

There are approx. 25+ key companies which are developing the therapies for Methicillin-Resistant Staphylococcus Aureus Infections. The companies which have their Methicillin-Resistant Staphylococcus Aureus Infections drug candidates in the most advanced stage, i.e. phase II include, Helperby Therapeutics.

• Phases

DelveInsight’s report covers around 27+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Methicillin-Resistant Staphylococcus Aureus Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Methicillin-Resistant Staphylococcus Aureus Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Methicillin-Resistant Staphylococcus Aureus Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Methicillin-Resistant Staphylococcus Aureus Infections drugs.

Methicillin-Resistant Staphylococcus Aureus Infections Report Insights

• Methicillin-Resistant Staphylococcus Aureus Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Methicillin-Resistant Staphylococcus Aureus Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Methicillin-Resistant Staphylococcus Aureus Infections drugs?
• How many Methicillin-Resistant Staphylococcus Aureus Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Methicillin-Resistant Staphylococcus Aureus Infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Methicillin-Resistant Staphylococcus Aureus Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Methicillin-Resistant Staphylococcus Aureus Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Trellis Bioscience
• LegoChem Biosciences
• Aptorum Group
• ContraFect
• Crystalgenomics
• Cellics Therapeutics
• MicuRx
• Oxford Antibiotic Group
• Destiny Pharma
• TSRL, Inc.
• TAXIS Pharmaceuticals
• Basilea Pharmaceutica
• Helperby Therapeutics
• Akagera Medicines
• Histogen
• Alphamab Co. Ltd
• Biocidium Pharmaceuticals

Key Products

• TRL1068
• Delpazolid
• ALS 4
• Tonabacase
• Teicoplanin inhalation
• Research programme: antibacterials
• LTX 109
• CG 400549
• Research programme: anti-infective monoclonal antibodies
• SAAP 148
• Exebacase
• Marinus
• CTI 005
• Iclaprim
• MRX 4
• MRX 7
• XF-73
• TXA709
• ARV-1801
• AR-301
• ACX-375C
• ABX-605
• IBT-V02
• BCM-0184